Show simple item record

Authordc.contributor.authorGarcía González, Paulina 
Authordc.contributor.authorUbilla Olguín, Gabriela 
Authordc.contributor.authorCatalán Martina, Diego 
Authordc.contributor.authorSchinnerling, Katina 
Authordc.contributor.authorAguillón Gutiérrez, Juan Carlos 
Admission datedc.date.accessioned2017-11-21T15:08:52Z
Available datedc.date.available2017-11-21T15:08:52Z
Publication datedc.date.issued2016
Cita de ítemdc.identifier.citationAutoimmunity Reviews 15 (2016) 1071–1080es_ES
Identifierdc.identifier.other10.1016/j.autrev.2016.07.032
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/145714
Abstractdc.description.abstractDendritic cells (DCs) control immune responses by driving potent inflammatory actions against external and internal threats while generating tolerance to self and harmless components. This duality and their potential to reprogram immune responses in an antigen-specific fashion have made them an interesting target for immunotherapeutic strategies to control autoimmune diseases. Several protocols have been described for in vitro generation of tolerogenic DCs (tolDCs) capable of modulating adaptive immune responses and restoring tolerance through different mechanisms that involve anergy, generation of regulatory lymphocyte populations, or deletion of potentially harmful inflammatory T cell subsets. Recently, the capacity of tolDCs to induce interleukin (IL-10)-secreting regulatory B cells has been demonstrated. In vitro assays and rodent models of autoimmune diseases provide insights to the molecular regulators and pathways enabling tolDCs to control immune responses. Here we review mechanisms through which tolDCs modulate adaptive immune responses, particularly focusing on their suitability for reprogramming autoreactive CD4(+) effector T cells. Furthermore, we discuss recent findings establishing that tolDCs also modulate B cell populations and discuss clinical trials applying tolDCs to patients with autoimmune diseases.es_ES
Patrocinadordc.description.sponsorshipFondecyt-Chile 1140553 Millennium Institute on Immunology and Immunotherapy P09-016-F Fundacion Ciencia Translational from Chilees_ES
Lenguagedc.language.isoenes_ES
Publisherdc.publisherElsevieres_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
Sourcedc.sourceAutoimmunity Reviewses_ES
Títulodc.titleTolerogenic dendritic cells for reprogramming of lymphocyte responses in autoimmune diseaseses_ES
Document typedc.typeArtículo de revista
Catalogueruchile.catalogadorlajes_ES
Indexationuchile.indexArtículo de publicación ISIes_ES


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile